<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04269811</url>
  </required_header>
  <id_info>
    <org_study_id>RJH-Myeloid-2020</org_study_id>
    <nct_id>NCT04269811</nct_id>
  </id_info>
  <brief_title>Flu-Bu-Mel Conditioning Regimen for Myeloid Disease</brief_title>
  <official_title>Phase Study ofFlu-Bu-Mel Conditioning Regimen for Patients With Myeloid Disease Undergoing Allogeneic Stem Cell Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Jiao Tong University School of Medicine</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Jiao Tong University School of Medicine</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing&#xD;
      allo-HSCT, the conditioning regimen will be 5-day Fludarabine, 2-day Busulifan and 2-day&#xD;
      melphalan&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      For patients with acute myeloid leukemia (AML) or myelodyspasia syndrome undergoing&#xD;
      allo-HSCT, the conditioning regimen will be Fludarabine (30mg/m2, d-7 to d-3) + Busulifan&#xD;
      3.2mg/kg (d-7 to d-6) + melphalan 70mg/m2 (d-4 and d-3). The GVHD prophylaxis will be PT-CY&#xD;
      (Cyclophosphamide 50mg/kg d+3 and d+4) + low-dose ATG (2.5mg/kg) on d+15.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 15, 2020</start_date>
  <completion_date type="Anticipated">December 30, 2022</completion_date>
  <primary_completion_date type="Actual">June 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>disease-free survival (DFS)</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>From transplantation to documentation of death or relapse or progression</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Overall survival (OS)</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>From transplantation to documentation of death due to any causes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Relapse rate</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>From transplantation to documentation of relapse or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>non-relapse mortality (NRM)</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>From transplantation to documentation of death not due to disease relapse or progression</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>acute graft versus host disease (aGVHD)</measure>
    <time_frame>day 180 after transplantation</time_frame>
    <description>Incidence of documented grade II-IV acute GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>chronic graft versus host disease (cGVHD)</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>Incidence of documented moderate to severe chronic GVHD</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>relapse free survival (GRFS)</measure>
    <time_frame>1 year after transplantation</time_frame>
    <description>From transplantation to documentation of death, III-IV aGVHD, moderate to severe chronic GVHD and relapse</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">49</enrollment>
  <condition>Relapse Rate After Allo-HSCT</condition>
  <arm_group>
    <arm_group_label>Flu-Bu-Mel</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fludarabine 150mg/m2 + Busulfan 3.2mg/kg 2 days + melphalan 50-70mg/m2</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Flu-Bu-Mel</intervention_name>
    <description>5-day fludarabine + 2-day busulfan (3.2mg/kg) + 2-day melphalan (50-70mg/m2)</description>
    <arm_group_label>Flu-Bu-Mel</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  acute myeloid leukemia (CR1 or CR2) or myelodysplasia syndrome&#xD;
&#xD;
          -  patients with HLA matched sibling, unrelated or Haplo-identical donor&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  patients with active infection&#xD;
&#xD;
          -  patients with abnormal liver function damage: ALT/AST above 2X normal range&#xD;
&#xD;
          -  patients with abnormal renal function damage Scr&gt;160µmol/L;&#xD;
&#xD;
          -  patients with insufficient pulmonary function (FEV1，FVC，DLCO&lt;50%）and heart failure or&#xD;
             with EF &lt;50%)&#xD;
&#xD;
          -  patients with mental instability or unwilling to give inform consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jion HU</last_name>
    <role>Principal Investigator</role>
    <affiliation>Head BMT program, Rui Jin Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Blood &amp; Marrow Transplantation Center, RuiJin Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200025</zip>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Shanghai No6 Hospital</name>
      <address>
        <city>Shanghai</city>
        <country>China</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>June 2021</verification_date>
  <study_first_submitted>February 12, 2020</study_first_submitted>
  <study_first_submitted_qc>February 13, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">February 17, 2020</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Shanghai Jiao Tong University School of Medicine</investigator_affiliation>
    <investigator_full_name>Jiong HU</investigator_full_name>
    <investigator_title>Head, Blood &amp; Marrow Transplantation Center</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Recurrence</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

